Edition:
United Kingdom

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

65.42USD
8:59pm GMT
Change (% chg)

$0.91 (+1.41%)
Prev Close
$64.51
Open
$64.73
Day's High
$65.80
Day's Low
$63.63
Volume
532,182
Avg. Vol
571,479
52-wk High
$102.60
52-wk Low
$58.33

Latest Key Developments (Source: Significant Developments)

Incyte Reports 2018 Q3 Financial Results
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Incyte Corp ::INCYTE REPORTS 2018 THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS.Q3 NON-GAAP EARNINGS PER SHARE $0.38.Q3 EARNINGS PER SHARE $0.14.Q3 EARNINGS PER SHARE VIEW $0.40 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL GAAP REVENUE $449.7 MILLION VERSUS $381.5 MILLION.SEES FY 2018 GAAP AND NON-GAAP JAKAFI NET PRODUCT REVENUES $1,370 MILLION - $1,400 MILLION.  Full Article

FDA Grants priority review for Ruxolitinib (Jakafi) as a treatment for patients with acute graft-versus-host disease
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Incyte Corp ::FDA GRANTS PRIORITY REVIEW FOR RUXOLITINIB (JAKAFI) AS A TREATMENT FOR PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.FDA GRANTS PRIORITY REVIEW FOR RUXOLITINIB (JAKAFI) AS A TREATMENT FOR PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - DESIGNATION SHORTENS FDA REVIEW PERIOD TO SIX MONTHS COMPARED TO 10 MONTHS FOR STANDARD REVIEW.INCYTE CORP - FDA HAS GRANTED RUXOLITINIB ORPHAN DRUG DESIGNATION FOR TREATMENT OF GVHD.  Full Article

Eli Lilly And Co Shares Updated Safety Analysis Of Olumiant In Patients With Moderately-To-Severely Active Rheumatoid Arthritis
Sunday, 21 Oct 2018 

Oct 21 (Reuters) - Eli Lilly And Co LLY.O::ELI LILLY AND CO -LILLY SHARES UPDATED SAFETY ANALYSIS OF OLUMIANT® (BARICITINIB) IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS.ELI LILLY AND CO SAYS INTEGRATED SAFETY ANALYSIS REFLECTS LONG-TERM RESULTS FROM 3,492 TREATED PATIENTS FOR 7,860 PATIENT-YEARS OF EXPOSURE.ELI LILLY AND CO -OVERALL, ADVERSE EVENT IRS PER 100 PYE WERE CONSISTENT WITH PRIOR ANALYSES, DID NOT SHOW EVIDENCE OF INCREASE WITH LONGER-TERM TREATMENT..ELI LILLY AND CO SAYS FOLLOW UP INVESTIGATIONS WILL CONTINUE TO ASSESS OLUMIANT'S LONG-TERM SAFETY PROFILE, INCLUDING MALIGNANCIES, VTE AND MACE..ELI LILLY AND CO SAYS FEWER THAN 1.0 PERCENT OF PATIENTS DISCONTINUED TREATMENT WITH OLUMIANT DUE TO ABNORMAL LAB RESULTS.  Full Article

Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Incyte Corp ::PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC.ADVERSE EVENTS (AES) WERE CONSISTENT WITH PREVIOUSLY REPORTED DATA AND NO NEW SAFETY SIGNALS WERE OBSERVED IN STUDY.CLINICAL FINDINGS FROM ONGOING STUDY INDICATE SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY REPORTED DATA RESULTS.NOVARTIS HAS EXCLUSIVE DEVELOPMENT & COMMERCIALIZATION WORLDWIDE RIGHTS TO CAPMATINIB.  Full Article

Agenus Inc Entered Royalty Purchase Agreement With XOMA
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Agenus Inc ::AGENUS INC - ON SEPTEMBER 20, CO, UNIT ENTERED ROYALTY PURCHASE AGREEMENT WITH XOMA (US) LLC.AGENUS - XOMA PAID $15.0 MILLION FOR RIGHT TO GET 33% FUTURE ROYALTIES & 10% FUTURE MILESTONES CO ENTITLED TO GET FROM INCYTE, MERCK.AGENUS - DEAL WITH XOMA EXCLUDES NEXT MILESTONE CO EXPECTS TO GET FROM INCYTE IN Q4 2018.  Full Article

Incyte Says Mid-Stage Graft-Versus-Host Disease Trial For Jakafi Met Main Goal
Thursday, 21 Jun 2018 

June 21 (Reuters) - Incyte Corp ::INCYTE ANNOUNCES REACH1 PIVOTAL TRIAL MEETS PRIMARY ENDPOINT OF OVERALL RESPONSE RATE FOR RUXOLITINIB (JAKAFI®) IN STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - PLANS TO SNDA FOR APPROVAL OF RUXOLITINIB FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD WITH U.S. FDA DURING Q3 OF 2018.  Full Article

Immunovaccine And Incyte Expand Clinical Collaboration
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER.IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE.IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL.IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018.  Full Article

Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Incyte Corp ::INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT.INCYTE-‍UNDER AGREEMENT, SYROS TO USE ITS GENE CONTROL PLATFORM TO IDENTIFY NOVEL THERAPEUTIC TARGETS WITH FOCUS IN MYELOPROLIFERATIVE NEOPLASMS​.INCYTE - CO TO HAVE EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE ANY THERAPIES UNDER COLLABORATION THAT MODULATE VALIDATED TARGETS​.INCYTE - UNDER DEAL, CO TO GET OPTIONS TO GET EXCLUSIVE WORLDWIDE RIGHTS TO INTELLECTUAL PROPERTY FROM COLLABORATION FOR UP TO SEVEN VALIDATED TARGETS.INCYTE CORP - ‍ UNDER TERMS , CO TO PAY SYROS $10 MILLION UPFRONT AND PURCHASE A TOTAL OF $10 MILLION IN SYROS COMMON STOCK AT $12.61 PER SHARE​.INCYTE - SHOULD INCYTE EXERCISE ALL OF ITS OPTIONS UNDER DEAL, SYROS COULD GET UP TO $54 MILLION FROM INCYTE IN TARGET SELECTION & OPTION EXERCISE FEES.INCYTE CORP - SYROS COULD ALSO RECEIVE UP TO $50 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES, AS WELL AS UP TO $65 MILLION IN COMMERCIAL MILESTONES.INCYTE CORP - SYROS WOULD ALSO BE ELIGIBLE TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON SALES OF PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Incyte Corp :Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia.Incyte Corp - ‍announced that first patient has been treated in reset pivotal trial evaluating Ruxolitinib​.  Full Article

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC